Fortrea Acquires Worldwide Clinical Trials’ Early Phase Division for $45M to Add 200-Bed CPU and GLP Bioanalytical Lab

• Fortrea (Nasdaq: FTRE), a leading global CRO, has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials — comprising a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, a 60,000 sq ft GLP bioanalytical laboratory in Austin, and a biospecimen storage facility in Pflugerville, Texas — in an all-cash transaction valued at approximately $45 million.

• The acquisition adds dedicated in-house large and small molecule bioanalytical capabilities to Fortrea’s Clinical Pharmacology Services business unit, enabling integrated execution of early-phase studies under a single CRO roof — while freeing Worldwide Clinical Trials to accelerate investment in its rapidly growing late-stage oncology, neuroscience, internal medicine, and rare disease therapeutic business.

Fortrea (Nasdaq: FTRE), a leading global CRO, and Worldwide Clinical Trials announced on September 2, 2026, from Durham and Research Triangle Park, North Carolina, that they have signed a definitive agreement under which Fortrea will acquire Worldwide’s Early Phase Services division in an all-cash transaction valued at approximately $45 million. The Early Phase Services division encompasses three Texas-based facilities: a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, a 60,000 sq ft GLP-compliant bioanalytical laboratory in Austin, and a biospecimen storage facility in Pflugerville — together constituting an integrated early-phase CRO infrastructure supporting drug candidates from first-in-human studies through later-stage clinical research.

The strategic logic of the acquisition centers on eliminating a critical operational handoff within early clinical development. By adding in-house large and small molecule bioanalytical capabilities directly adjacent to its existing Clinical Pharmacology Services business, Fortrea eliminates the separation between PK sample collection and bioanalytical processing that typically introduces delays and operational coordination burden in early-phase CRO studies. The integrated model enables faster turnaround times, reduces the logistical complexity of coordinating between clinical and analytical functions, and supports both simple and highly complex study designs — including those requiring specialized volunteer populations, extended bedspace, or simultaneous clinical and bioanalytical operations — under a unified CRO infrastructure.

For Worldwide Clinical Trials, the divestiture of its Early Phase division is framed as a strategic concentration decision rather than a retreat. Worldwide retains the ability to support healthy volunteer studies globally through its external site network under a strategic alliance agreement with Fortrea that is intended to maintain continuity of operations, study delivery, and customer support throughout the transition. The divestiture frees capital and management bandwidth for Worldwide to accelerate investment in its rapidly growing late-stage therapeutic businesses across oncology, neuroscience, rare disease, and internal medicine — areas where the company’s more than 4,500 professionals operating across 70+ countries have built significant therapeutic depth and sponsor relationships.

The transaction will be structured to preserve operational continuity across current programs. Fortrea and Worldwide intend to enter a series of transition and services agreements to maintain project momentum, protect specialized capabilities, and provide a seamless customer experience during and after the transition. Upon closing — which remains subject to regulatory and license approvals — the Early Phase Services division will become part of Fortrea’s Clinical Pharmacology Services business unit, joining Fortrea’s existing early clinical development network and reinforcing the front end of what the company describes as an end-to-end development platform spanning Phase I through Phase IV and post-approval evidence generation. Barclays is serving as Fortrea’s financial advisor with Mintz Levin as legal counsel; BroadOak Partners is advising Worldwide with Greenberg Traurig as legal counsel.

“Fortrea is making an important investment in early clinical development as part of our end-to-end clinical development platform supporting customers from first-in-human studies through Phase IV and post-approval evidence generation. By bringing together complementary bioanalytical and clinical research offerings, we will enable a more seamless development experience for customers, broaden our scientific and operational capabilities and support studies of greater scale, complexity and scientific sophistication across a wider range of therapeutic needs.”

Anshul Thakral, Chief Executive Officer, Fortrea